VTGN icon

VistaGen Therapeutics
VTGN

Overview Fund Activity

14 hedge funds and large institutions have $2.79M invested in VistaGen Therapeutics in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.

Holders
14
Holders Change
–
Holders Change %
0%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
SFM
1
Sphera Funds Management
Israel
$1.69M
2
Citadel Advisors
2
Citadel Advisors
Florida
$21K
3
BC
3
Bartlett & Co
Ohio
$16K
4
Vanguard Group
4
Vanguard Group
Pennsylvania
$65K

Top Sellers

1
SM
1
Sabby Management
Florida
$0
2
TRCT
2
Tower Research Capital (TRC)
New York
$0
Name Market Value Shares Shares
Change 		Shares
Change %
SFM
1
Sphera Funds Management
Israel
$1.69M 1,058,386 +514,286 +95%
Parallax Volatility Advisers
2
Parallax Volatility Advisers
California
$441K 275,848 – –
NC
3
Nexthera Capital
New York
$221K 138,132 – –
DADC
4
D.A. Davidson & Co
Montana
$157K 98,500 – –
LTFS
5
Ladenburg Thalmann Financial Services
Florida
$72K 45,076 – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$65K 40,750 +3,723 +10%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$48K 30,097 – –
HighTower Advisors
8
HighTower Advisors
Illinois
$32K 20,215 – –
Citadel Advisors
9
Citadel Advisors
Florida
$21K 13,390 +13,390 New
Northern Trust
10
Northern Trust
Illinois
$17K 10,918 – –
BC
11
Bartlett & Co
Ohio
$16K 10,000 +10,000 New
HFM
12
Hartford Financial Management
Connecticut
$2K 1,300 – –
SM
13
Sabby Management
Florida
– – -25,537 Closed
UBS Group
14
UBS Group
Switzerland
$0 191 -5,896 -97%
TRCT
15
Tower Research Capital (TRC)
New York
– – -579 Closed
PCP
16
Proficio Capital Partners
Massachusetts
$0 89 – –